A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Capecitabine; Sunitinib

Criteria

Inclusion Criteria:

• Locally advanced or metastatic disease that can be measured. Patients with bone-only disease are also allowed to enter the study.

• Previous treatment with an anthracycline and a taxane in any setting

• Progression on first or second line regimen or adjuvant regimen if disease free interval less than 12 months

Exclusion Criteria:

• History of inflammatory carcinoma if there is no other measurable disease

• More than 2 chemotherapy agents in the advanced disease setting

• Brain metastases